3 February 2022PatentsAlex Baldwin

Hirshfeld defends IPR review authority under Arthrex

The acting director of the US Patent and Trademark Office (USPTO) Andrew Hirshfeld has defended his right to review final Patent Trial and Appeal Board (PTAB) decisions under Arthrex.

Already registered?

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More on this story

Patents

Hirshfeld grants first USPTO director review after Arthrex

4 November 2021 The acting director of the US Patent and Trademark Office Drew Hirshfeld has agreed for the first time to review a final written decision from the Patent Trial and Appeal Board (PTAB) after being given oversight over the board’s rulings in the Supreme Court’s Arthrex decision.

Patents

Drew Hirshfeld: boosting quality and quantity at the USPTO

26 February 2018 Despite concerns over patent quality and with at least one rising backlog, there are positives for the USPTO to focus on, as commissioner for patents Drew Hirshfeld tells WIPR.

UK-India trade deal is ‘missed opportunity’, say industry bodies

WATCH: Recent developments in design patent law

SEPs now searchable on WIPO’s global patent database

INTA 2025: San Diego to host largest post-COVID Annual Meeting

'Nothing can stand in the way of our work': Ukraine resumes IP system

Foley adds five-partner team from Perkins Coie and K&L Gates

WATCH: Finding a new balance in IP protection with trade secret protection

Optis v Apple: How the court calculated the royalty rate

Hirshfeld defends IPR review authority under Arthrex

More on this story

Editor's picks

Editor's picks

More articles